Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
XO/URAT1 Dual Inhibitor by BioSeedin for Hyperuricemia: Likelihood of Approval
XO/URAT1 Dual Inhibitor is under clinical development by BioSeedin and currently in Phase I for Hyperuricemia. According to GlobalData, Phase...